SG10201910987SA - Crispr-based genome modification and regulation - Google Patents

Crispr-based genome modification and regulation

Info

Publication number
SG10201910987SA
SG10201910987SA SG10201910987SA SG10201910987SA SG10201910987SA SG 10201910987S A SG10201910987S A SG 10201910987SA SG 10201910987S A SG10201910987S A SG 10201910987SA SG 10201910987S A SG10201910987S A SG 10201910987SA SG 10201910987S A SG10201910987S A SG 10201910987SA
Authority
SG
Singapore
Prior art keywords
crispr
regulation
genome modification
based genome
modification
Prior art date
Application number
SG10201910987SA
Other languages
English (en)
Inventor
Fuqiang Chen
Gregory D Davis
Original Assignee
Sigma Aldrich Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50883989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201910987S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Aldrich Co Llc filed Critical Sigma Aldrich Co Llc
Publication of SG10201910987SA publication Critical patent/SG10201910987SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201910987SA 2012-12-06 2013-12-05 Crispr-based genome modification and regulation SG10201910987SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734256P 2012-12-06 2012-12-06
US201361758624P 2013-01-30 2013-01-30
US201361761046P 2013-02-05 2013-02-05
US201361794422P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
SG10201910987SA true SG10201910987SA (en) 2020-01-30

Family

ID=50883989

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201910987SA SG10201910987SA (en) 2012-12-06 2013-12-05 Crispr-based genome modification and regulation
SG11201503824SA SG11201503824SA (en) 2012-12-06 2013-12-05 Crispr-based genome modification and regulation
SG10201800585VA SG10201800585VA (en) 2012-12-06 2013-12-05 Crispr-based genome modification and regulation
SG10202107423UA SG10202107423UA (en) 2012-12-06 2013-12-05 Crispr-based genome modification and regulation

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG11201503824SA SG11201503824SA (en) 2012-12-06 2013-12-05 Crispr-based genome modification and regulation
SG10201800585VA SG10201800585VA (en) 2012-12-06 2013-12-05 Crispr-based genome modification and regulation
SG10202107423UA SG10202107423UA (en) 2012-12-06 2013-12-05 Crispr-based genome modification and regulation

Country Status (17)

Country Link
US (15) US20160017366A1 (ko)
EP (11) EP3138910B1 (ko)
JP (6) JP6620018B2 (ko)
KR (7) KR20230070065A (ko)
CN (3) CN105142669B (ko)
AU (9) AU2013355214B2 (ko)
BR (1) BR112015012375A2 (ko)
CA (3) CA2977152C (ko)
DK (6) DK3138911T3 (ko)
ES (6) ES2769310T3 (ko)
HK (1) HK1218389A1 (ko)
IL (5) IL300199A (ko)
LT (4) LT3138911T (ko)
PL (6) PL3138910T3 (ko)
PT (6) PT3138912T (ko)
SG (4) SG10201910987SA (ko)
WO (1) WO2014089290A1 (ko)

Families Citing this family (364)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027558A2 (en) 2006-08-31 2008-03-06 Codon Devices, Inc. Iterative nucleic acid assembly using activation of vector-encoded traits
CN103502448B (zh) 2010-11-12 2017-03-29 Gen9股份有限公司 核酸合成的方法和设备
WO2012064975A1 (en) 2010-11-12 2012-05-18 Gen9, Inc. Protein arrays and methods of using and making the same
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2013032850A2 (en) 2011-08-26 2013-03-07 Gen9, Inc. Compositions and methods for high fidelity assembly of nucleic acids
US11021737B2 (en) 2011-12-22 2021-06-01 President And Fellows Of Harvard College Compositions and methods for analyte detection
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
US9150853B2 (en) 2012-03-21 2015-10-06 Gen9, Inc. Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
EP4001427A1 (en) 2012-04-24 2022-05-25 Gen9, Inc. Methods for sorting nucleic acids and multiplexed preparative in vitro cloning
PL2847335T3 (pl) 2012-04-25 2019-01-31 Regeneron Pharmaceuticals, Inc. Celowanie dużymi wektorami do celowania wspomagane nukleazą
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
DE202013012242U1 (de) 2012-05-25 2016-02-02 Emmanuelle Charpentier Zusammensetzungen für die durch RNA gesteuerte Modifikation einer Ziel-DNA und für die durch RNA gesteuerte Modulation der Transkription
CA2877290A1 (en) 2012-06-19 2013-12-27 Daniel F. Voytas Gene targeting in plants using dna viruses
CN113512577A (zh) 2012-06-25 2021-10-19 Gen9股份有限公司 用于核酸组装和高通量测序的方法
CN105188767A (zh) * 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
DE202013012597U1 (de) 2012-10-23 2017-11-21 Toolgen, Inc. Zusammensetzung zum Spalten einer Ziel-DNA, umfassend eine für die Ziel-DNA spezifische guide-RNA und eine Cas-Protein-codierende Nukleinsäure oder ein Cas-Protein, sowie deren Verwendung
WO2014078819A2 (en) 2012-11-16 2014-05-22 Transposagen Biopharmaceuticals, Inc. Site-specific enzymes and methods of use
PL3138910T3 (pl) 2012-12-06 2018-01-31 Sigma Aldrich Co Llc Oparta na CRISPR modyfikacja i regulacja genomu
MX2015007549A (es) * 2012-12-12 2017-01-20 Broad Inst Inc Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
JP6552965B2 (ja) * 2012-12-12 2019-07-31 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための改善された系、方法および酵素組成物のエンジニアリングおよび最適化
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
PL2931898T3 (pl) 2012-12-12 2016-09-30 Le Cong Projektowanie i optymalizacja systemów, sposoby i kompozycje do manipulacji sekwencją z domenami funkcjonalnymi
EP3434776A1 (en) 2012-12-12 2019-01-30 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US20140189896A1 (en) 2012-12-12 2014-07-03 Feng Zhang Crispr-cas component systems, methods and compositions for sequence manipulation
WO2014099744A1 (en) * 2012-12-17 2014-06-26 President And Fellows Of Harvard College Rna-guided human genome engineering
JP2016507244A (ja) * 2013-02-27 2016-03-10 ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） Ｃａｓ９ヌクレアーゼによる卵母細胞における遺伝子編集
US10138509B2 (en) 2013-03-12 2018-11-27 President And Fellows Of Harvard College Method for generating a three-dimensional nucleic acid containing matrix
WO2014150624A1 (en) 2013-03-14 2014-09-25 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
MX2015011985A (es) * 2013-03-15 2016-04-07 Univ Minnesota Ingenieria genomica de plantas utilizando sistemas crispr/cas.
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
KR102210319B1 (ko) * 2013-03-15 2021-02-01 더 제너럴 하스피탈 코포레이션 특정 게놈 좌위에 대한 유전적 및 후성적 조절 단백질의 rna-안내 표적화
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US20160186208A1 (en) * 2013-04-16 2016-06-30 Whitehead Institute For Biomedical Research Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
HUE040575T2 (hu) 2013-04-16 2019-03-28 Regeneron Pharma A patkány genom célzott módosítása
CN105683376A (zh) * 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
JP7065564B2 (ja) * 2013-05-29 2022-05-12 セレクティス Ｃａｓ９ニッカーゼ活性を用いて正確なｄｎａ切断をもたらすための方法
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
WO2014197568A2 (en) 2013-06-04 2014-12-11 President And Fellows Of Harvard College Rna-guideded transcriptional regulation
EP3539573B1 (en) * 2013-06-05 2024-02-14 Duke University Rna-guided gene editing and gene regulation
JP2016521561A (ja) 2013-06-14 2016-07-25 セレクティス 植物における非トランスジェニックのゲノム編集のための方法
WO2014204727A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
EP3011032B1 (en) * 2013-06-17 2019-10-16 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
KR20160034901A (ko) * 2013-06-17 2016-03-30 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작에 최적화된 ｃｒｉｓｐｒ-ｃａｓ 이중 닉카아제 시스템, 방법 및 조성물
BR112015031608A2 (pt) * 2013-06-17 2017-08-22 Massachusetts Inst Technology Aplicação e uso dos sistemas crispr-cas, vetores e composições para direcionamento e terapia hepáticos
RU2716421C2 (ru) * 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка, применение и применения в терапии систем crispr-cas и композиций для целенаправленного воздействия на нарушения и заболевания с использованием вирусных компонентов
AU2014281026B2 (en) 2013-06-17 2020-05-28 Massachusetts Institute Of Technology Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
EP3611268A1 (en) 2013-08-22 2020-02-19 E. I. du Pont de Nemours and Company Plant genome modification using guide rna/cas endonuclease systems and methods of use
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
DE202014010413U1 (de) 2013-09-18 2015-12-08 Kymab Limited Zellen und Organismen
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
WO2015066119A1 (en) 2013-10-30 2015-05-07 North Carolina State University Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
DK3066201T3 (en) 2013-11-07 2018-06-06 Editas Medicine Inc CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES
EP4349980A2 (en) 2013-12-11 2024-04-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
MX2016007654A (es) 2013-12-11 2017-08-15 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
SG10201804974RA (en) 2013-12-12 2018-07-30 Broad Inst Inc Compositions and Methods of Use of Crispr-Cas Systems in Nucleotide Repeat Disorders
KR20160097327A (ko) 2013-12-12 2016-08-17 더 브로드 인스티튜트, 인코퍼레이티드 유전자 산물, 구조 정보 및 유도성 모듈형 ｃａｓ 효소의 발현의 변경을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 방법
BR112016013201B1 (pt) 2013-12-12 2023-01-31 The Broad Institute, Inc. Uso de uma composição compreendendo um sistema crispr-cas no tratamento de uma doença genética ocular
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
EP3080271B1 (en) 2013-12-12 2020-02-12 The Broad Institute, Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
US10787654B2 (en) * 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
PL3105328T3 (pl) 2014-02-11 2020-10-19 The Regents Of The University Of Colorado, A Body Corporate Umożliwiana przez CRISPR multipleksowa modyfikacja genomu
JP2017506893A (ja) 2014-02-18 2017-03-16 デューク ユニバーシティ ウイルス複製不活化組成物並びにその製造方法及び使用
WO2015134812A1 (en) 2014-03-05 2015-09-11 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US9938521B2 (en) 2014-03-10 2018-04-10 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015148670A1 (en) * 2014-03-25 2015-10-01 Editas Medicine Inc. Crispr/cas-related methods and compositions for treating hiv infection and aids
US11242525B2 (en) 2014-03-26 2022-02-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating sickle cell disease
JP2017512481A (ja) 2014-04-08 2017-05-25 ノースカロライナ ステート ユニバーシティーＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｃｒｉｓｐｒ関連遺伝子を用いた、ｒｎａ依存性の転写抑制のための方法および組成物
WO2015188056A1 (en) * 2014-06-05 2015-12-10 Sangamo Biosciences, Inc. Methods and compositions for nuclease design
LT3152312T (lt) 2014-06-06 2020-04-27 Regeneron Pharmaceuticals, Inc. Tikslinio lokuso modifikavimo būdai ir kompozicijos
CN106852157B (zh) * 2014-06-16 2022-04-12 约翰斯·霍普金斯大学 用于使用h1启动子表达crispr向导rna的组合物和方法
EP3157328B1 (en) * 2014-06-17 2021-08-04 Poseida Therapeutics, Inc. A method for directing proteins to specific loci in the genome and uses thereof
HUE049405T2 (hu) * 2014-06-23 2020-09-28 Regeneron Pharma Nukleáz-közvetített DNS-összeállítás
HUE041584T2 (hu) 2014-06-26 2019-05-28 Regeneron Pharma Célzott genetikai módosítások és alkalmazási módszerek és készítmények
US20170198268A1 (en) * 2014-07-09 2017-07-13 Gen9, Inc. Compositions and Methods for Site-Directed DNA Nicking and Cleaving
EP3169776A4 (en) * 2014-07-14 2018-07-04 The Regents of The University of California Crispr/cas transcriptional modulation
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
CN106922154B (zh) 2014-08-06 2022-01-07 基因工具股份有限公司 使用空肠弯曲杆菌crispr/cas系统衍生的rna引导的工程化核酸酶的基因编辑
WO2016033298A1 (en) 2014-08-28 2016-03-03 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
US10570418B2 (en) 2014-09-02 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification
RU2017112324A (ru) 2014-09-12 2018-10-15 Пайонир Хай-Бред Интернэшнл, Инк. Создание сайтов сайт-специфической интеграции для сложных локусов признаков в кукурузе и сое, а также способы применения
US9879283B2 (en) * 2014-10-09 2018-01-30 Life Technologies Corporation CRISPR oligonucleotides and gene editing
CA2963840A1 (en) 2014-10-09 2016-04-14 Seattle Children's Hospital (dba Seattle Children's Research Institute) Long poly(a) plasmids and methods for introduction of long poly(a) sequences into the plasmid
PL3207124T3 (pl) 2014-10-15 2019-11-29 Regeneron Pharma Sposoby i kompozycje do wytwarzania lub utrzymywania komórek pluripotencjalnych
US20170306306A1 (en) * 2014-10-24 2017-10-26 Life Technologies Corporation Compositions and Methods for Enhancing Homologous Recombination
WO2016070037A2 (en) * 2014-10-31 2016-05-06 Massachusetts Institute Of Technology Massively parallel combinatorial genetics for crispr
CN107406838A (zh) 2014-11-06 2017-11-28 纳幕尔杜邦公司 Rna引导的内切核酸酶向细胞中的肽介导的递送
EP3215617B1 (en) 2014-11-07 2024-05-08 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
US20170369848A1 (en) * 2014-11-11 2017-12-28 Q Therapeutics, Inc. Engineering mesenchymal stem cells using homologous recombination
CN107109422B (zh) * 2014-11-19 2021-08-13 基础科学研究院 使用由两个载体表达的拆分的Cas9的基因组编辑
LT3221457T (lt) 2014-11-21 2019-06-10 Regeneron Pharmaceuticals, Inc. Nukreipiančios genetinės modifikacijos būdai ir kompozicijos, naudojant suporuotas kreipiančiąsias rnr sekas
GB201421096D0 (en) 2014-11-27 2015-01-14 Imp Innovations Ltd Genome editing methods
JP7068821B2 (ja) 2014-12-03 2022-05-17 アジレント・テクノロジーズ・インク 化学修飾を有するガイドｒｎａ
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
EP3985115A1 (en) 2014-12-12 2022-04-20 The Broad Institute, Inc. Protected guide rnas (pgrnas)
RU2707137C2 (ru) 2014-12-19 2019-11-22 Регенерон Фармасьютикалз, Инк. Способы и композиции для нацеленной генетической модификации посредством одноэтапного множественного нацеливания
WO2016100857A1 (en) 2014-12-19 2016-06-23 Regeneron Pharmaceuticals, Inc. Stem cells for modeling type 2 diabetes
EP3798302A1 (fr) 2015-01-29 2021-03-31 Meiogenix Procede pour induire des recombinaisons meiotiques ciblees
CN107787367B (zh) 2015-04-06 2021-10-26 里兰斯坦福初级大学理事会 用于crispr/cas介导的基因调控的化学修饰的引导rna
JP2018522249A (ja) 2015-04-24 2018-08-09 エディタス・メディシン、インコーポレイテッド Ｃａｓ９分子／ガイドｒｎａ分子複合体の評価
WO2016176617A2 (en) 2015-04-29 2016-11-03 New York University Method for treating high-grade gliomas
CN108026566A (zh) 2015-05-04 2018-05-11 特拉维夫大学拉莫特有限公司 用于使dna片段化的方法和试剂盒
WO2016182959A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
EA201792663A1 (ru) 2015-05-29 2018-04-30 Норт Каролина Стейт Юниверсити Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
EP3303585A4 (en) 2015-06-03 2018-10-31 Board of Regents of the University of Nebraska Dna editing using single-stranded dna
EP3307887A1 (en) 2015-06-09 2018-04-18 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
EP3307872B1 (en) 2015-06-15 2023-09-27 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
CA2989827A1 (en) * 2015-06-17 2016-12-22 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
CA2989830A1 (en) 2015-06-18 2016-12-22 The Broad Institute, Inc. Crispr enzyme mutations reducing off-target effects
CN107949400A (zh) * 2015-06-24 2018-04-20 西格马-奥尔德里奇有限责任公司 细胞周期依赖性基因组调控和修饰
CA2993431A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Nuclease based knockouts of immunological checkpoint genes in immune cells
AU2016309948B2 (en) 2015-08-14 2021-05-20 The University Of Sydney Connexin 45 inhibition for therapy
MX2018002339A (es) 2015-08-25 2018-12-19 Univ Duke Composiciones y metodos de mejora de la especificidad en ingenieria genomica usando endonucleasas guiadas por arn.
WO2017040348A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Engineered crispr-cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
WO2017053879A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
KR101745863B1 (ko) 2015-09-25 2017-06-12 전남대학교산학협력단 Crispr/cas9 시스템을 이용한 프로히비틴2 유전자 제거용 시발체
KR101795999B1 (ko) 2015-09-25 2017-11-09 전남대학교산학협력단 Crispr/cas9 시스템을 이용한 베타2-마이크로글로불린 유전자 제거용 시발체
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
ES2875602T3 (es) 2015-10-22 2021-11-10 Ericsson Telefon Ab L M Métodos y aparato relacionados con la mejora selectiva de señales de radio
IL310721A (en) * 2015-10-23 2024-04-01 Harvard College Nucleobase editors and their uses
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
CN108474022A (zh) 2015-11-03 2018-08-31 哈佛学院董事及会员团体 用于包含三维核酸的基质容积成像的设备和方法
CN106893739A (zh) 2015-11-17 2017-06-27 香港中文大学 用于靶向基因操作的新方法和系统
US10240145B2 (en) * 2015-11-25 2019-03-26 The Board Of Trustees Of The Leland Stanford Junior University CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
IL304088A (en) 2016-01-11 2023-08-01 Univ Leland Stanford Junior Systems containing chimeric proteins and their uses for controlling gene expression
JP7012645B2 (ja) 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
EP3433364A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
EP3433363A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
WO2017180694A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Cas9 fusion molecules gene editing systems, and methods of use thereof
AU2017250683A1 (en) * 2016-04-14 2018-11-01 Boco Silicon Valley, Inc. Genome editing of human neural stem cells using nucleases
CN109715803B (zh) * 2016-04-25 2023-07-07 巴塞尔大学 等位基因编辑及其应用
CA3022290A1 (en) 2016-04-25 2017-11-02 President And Fellows Of Harvard College Hybridization chain reaction methods for in situ molecular detection
RU2745563C2 (ru) 2016-05-20 2021-03-29 Регенерон Фармасьютикалс, Инк. Способы преодоления иммунологической толерантности с использованием множества направляющих рнк
CA3209273A1 (en) * 2016-06-02 2017-12-07 Sigma-Aldrich Co. Llc Using programmable dna binding proteins to enhance targeted genome modification
JP2019517503A (ja) * 2016-06-03 2019-06-24 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 遺伝子編集戦略によるｈｉｖ−１のネガティブフィードバック調節
BR112018074930A2 (pt) * 2016-06-03 2019-03-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) ácido nucleico, vetor de ácido nucleico, partícula de entrega, composição farmacêutica, célula hospedeira, método para edição do genoma e método e kit para prevenção e/ou tratamento de uma doença
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
US10337051B2 (en) 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
LT3474669T (lt) 2016-06-24 2022-06-10 The Regents Of The University Of Colorado, A Body Corporate Barkodu pažymėtų kombinatorinių bibliotekų generavimo būdai
WO2018013720A1 (en) * 2016-07-12 2018-01-18 Washington University Incorporation of internal polya-encoded poly-lysine sequence tags and their variations for the tunable control of protein synthesis in bacterial and eukaryotic cells
DK3491014T3 (da) 2016-07-28 2023-05-30 Regeneron Pharma Allel-specifik primer eller sonde, som er hybridiseret til et nucleinsyremolekyle, som koder for en GPR156 variant
KR20190041476A (ko) 2016-07-29 2019-04-22 리제너론 파마슈티칼스 인코포레이티드 C-절단된 피브릴린-1의 발현을 유도하는 돌연변이를 포함하는 마우스
EP3494220A1 (en) 2016-08-02 2019-06-12 Editas Medicine, Inc. Compositions and methods for treating cep290 associated disease
CA3032699A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11078481B1 (en) 2016-08-03 2021-08-03 KSQ Therapeutics, Inc. Methods for screening for cancer targets
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
CN109963945A (zh) * 2016-08-20 2019-07-02 阿维利诺美国实验室股份有限公司 单一向导rna、crispr/cas9系统及其使用方法
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11078483B1 (en) 2016-09-02 2021-08-03 KSQ Therapeutics, Inc. Methods for measuring and improving CRISPR reagent function
WO2018048827A1 (en) * 2016-09-07 2018-03-15 Massachusetts Institute Of Technology Rna-guided endonuclease-based dna assembly
CN106636197B (zh) * 2016-09-22 2019-09-03 南京市妇幼保健院 一种定向敲降斑马鱼基因组中多拷贝基因的方法
US20190225974A1 (en) 2016-09-23 2019-07-25 BASF Agricultural Solutions Seed US LLC Targeted genome optimization in plants
EP3523426A4 (en) 2016-09-30 2020-01-22 The Regents of The University of California RNA GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHOD FOR USE THEREOF
US20190233820A1 (en) * 2016-10-11 2019-08-01 Stemgenics, Inc. Nanoparticles functionalized with gene editing tools and related methods
CA3040481A1 (en) 2016-10-14 2018-04-19 The General Hospital Corporation Epigenetically regulated site-specific nucleases
CN110214180A (zh) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 核碱基编辑器的aav递送
GB201617559D0 (en) 2016-10-17 2016-11-30 University Court Of The University Of Edinburgh The Swine comprising modified cd163 and associated methods
EP3529359B1 (en) 2016-10-18 2023-12-13 Regents of the University of Minnesota Tumor infiltrating lymphocytes for use in therapy
KR20190072639A (ko) * 2016-11-02 2019-06-25 유니버시타트 바셀 세포 치료에 사용하기 위한 면역학적으로 식별 가능한 세포 표면 변이체
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
KR102151065B1 (ko) * 2016-12-23 2020-09-02 기초과학연구원 동물 배아의 염기 교정용 조성물 및 염기 교정 방법
US11859219B1 (en) 2016-12-30 2024-01-02 Flagship Pioneering Innovations V, Inc. Methods of altering a target nucleotide sequence with an RNA-guided nuclease and a single guide RNA
CA3049980A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
CN106978438B (zh) * 2017-02-27 2020-08-28 北京大北农生物技术有限公司 提高同源重组效率的方法
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
EP3596217A1 (en) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
CN110914426A (zh) 2017-03-23 2020-03-24 哈佛大学的校长及成员们 包含核酸可编程dna结合蛋白的核碱基编辑器
WO2018195129A1 (en) 2017-04-17 2018-10-25 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
US11834670B2 (en) 2017-04-19 2023-12-05 Global Life Sciences Solutions Usa Llc Site-specific DNA modification using a donor DNA repair template having tandem repeat sequences
CA3059956A1 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
WO2018209158A2 (en) 2017-05-10 2018-11-15 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2018218166A1 (en) 2017-05-25 2018-11-29 The General Hospital Corporation Using split deaminases to limit unwanted off-target base editor deamination
SG11201911597YA (en) 2017-06-05 2020-01-30 Regeneron Pharma B4galt1 variants and uses thereof
WO2018227114A1 (en) 2017-06-09 2018-12-13 Editas Medicine, Inc. Engineered cas9 nucleases
CA3067382A1 (en) 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
EP3644722A1 (en) 2017-06-27 2020-05-06 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized asgr1 locus
HRP20220615T1 (hr) 2017-06-30 2022-06-24 Inscripta, Inc. Postupci, moduli, instrumenti i sustavi za automatiziranu obradu stanica
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
AU2018311695A1 (en) * 2017-07-31 2020-01-16 Sigma-Aldrich Co. Llc Synthetic guide RNA for CRISPR/Cas activator systems
AU2018309716A1 (en) 2017-07-31 2020-01-16 Regeneron Pharmaceuticals, Inc. Cas-transgenic mouse embryonic stem cells and mice and uses thereof
CN111182790A (zh) 2017-07-31 2020-05-19 瑞泽恩制药公司 Crispr报告体非人类动物及其用途
AU2018309714A1 (en) 2017-07-31 2020-01-30 Regeneron Pharmaceuticals, Inc. Assessment of CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo
IL310452A (en) * 2017-08-09 2024-03-01 Ricetec Inc Preparations and methods for genome modification
US10738327B2 (en) 2017-08-28 2020-08-11 Inscripta, Inc. Electroporation cuvettes for automation
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US20200216860A1 (en) * 2017-09-05 2020-07-09 Regeneron Pharmaceuticals, Inc. Delivery of a gene-editing system with a single retroviral particle and methods of generation and use
SG11202001754RA (en) 2017-09-06 2020-03-30 Regeneron Pharma Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
SG11202001792UA (en) 2017-09-07 2020-03-30 Regeneron Pharma Solute carrier family 14 member 1 (slc14a1) variants and uses thereof
EP4276185A3 (en) 2017-09-29 2024-02-21 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
US10443074B2 (en) 2017-09-30 2019-10-15 Inscripta, Inc. Modification of cells by introduction of exogenous material
AU2018352592A1 (en) 2017-10-16 2020-06-04 Beam Therapeutics, Inc. Uses of adenosine base editors
WO2019079195A1 (en) * 2017-10-16 2019-04-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education GENETICALLY MODIFIED MESENCHYMAL STEM CELLS FOR USE IN CARDIOVASCULAR PROSTHESES
JP2021501601A (ja) 2017-10-16 2021-01-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． コルヌリン（ｃｒｎｎ）バリアント及びその使用
BR112020008201A2 (pt) 2017-10-27 2020-10-06 The Regents Of The University Of California substituição-alvo de receptores de células t endógenos
US11970719B2 (en) 2017-11-01 2024-04-30 The Regents Of The University Of California Class 2 CRISPR/Cas compositions and methods of use
CN111565566B (zh) 2017-11-10 2022-10-21 瑞泽恩制药公司 包含slc30a8突变的非人动物及使用方法
US20210180059A1 (en) * 2017-11-16 2021-06-17 Astrazeneca Ab Compositions and methods for improving the efficacy of cas9-based knock-in strategies
CN116064611A (zh) 2017-11-30 2023-05-05 瑞泽恩制药公司 包含人源化trkb基因座的非人动物
WO2019126578A1 (en) * 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
US11293019B2 (en) 2017-12-22 2022-04-05 Gflas Life Sciences, Inc. Chimeric genome engineering molecules and methods
CA3086620A1 (en) 2018-01-12 2019-07-18 Basf Se Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
WO2019147302A1 (en) * 2018-01-26 2019-08-01 Bauer Daniel E Targeting bcl11a distal regulatory elements with a cas9-cas9 fusion for fetal hemoglobin reinduction
BR112020010479A2 (pt) 2018-02-15 2020-11-24 Sigma-Aldrich Co. Llc sistemas cas9 geneticamente modificados para modificação de genoma eucariótico
CA3089331A1 (en) 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
EP3775159A4 (en) 2018-03-29 2022-01-19 Inscripta, Inc. AUTOMATED REGULATION OF CELL GROWTH RATES FOR INDUCTION AND TRANSFORMATION
WO2019200004A1 (en) 2018-04-13 2019-10-17 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
GB2587970B (en) 2018-04-19 2023-02-08 Univ California Compositions and methods for gene editing
WO2019209926A1 (en) 2018-04-24 2019-10-31 Inscripta, Inc. Automated instrumentation for production of peptide libraries
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
CA3098489A1 (en) * 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Therapeutic genome editing in x-linked hyper igm syndrome
SG11202010837XA (en) 2018-05-10 2020-11-27 Auxolytic Ltd Gene therapy methods and compositions using auxotrophic regulatable cells
WO2019213910A1 (en) * 2018-05-10 2019-11-14 Syngenta Participations Ag Methods and compositions for targeted editing of polynucleotides
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
EP3575402A1 (en) * 2018-06-01 2019-12-04 Algentech SAS Gene targeting
CN112384063A (zh) 2018-06-07 2021-02-19 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 再生及转殖大麻的方法
WO2019234754A1 (en) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Nucleic acid constructs and methods of using same
WO2020005846A1 (en) * 2018-06-25 2020-01-02 Bionano Genomics, Inc. Labeling of dna
US20210277379A1 (en) * 2018-08-03 2021-09-09 Beam Therapeutics Inc. Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence
GB201813011D0 (en) 2018-08-10 2018-09-26 Vib Vzw Means and methods for drought tolerance in crops
IL292273B2 (en) 2018-08-14 2023-10-01 Inscripta Inc Devices, modules and methods for improved detection of edited sequences in living cells
US10752874B2 (en) 2018-08-14 2020-08-25 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
KR102103104B1 (ko) 2018-08-16 2020-04-22 (주)라트바이오 유전자 편집된 형질전환 동물 및 형질전환 배아
KR20210046001A (ko) * 2018-08-21 2021-04-27 시그마-알드리치 컴퍼니., 엘엘씨 시토졸 dna 센서 경로의 하향-조절
CA3108892A1 (en) 2018-08-30 2020-04-23 Inscripta, Inc. Improved detection of nuclease edited sequences in automated modules and instruments
CN109055379B (zh) * 2018-09-10 2022-04-15 石铭 一种转基因鸡输卵管生物反应器的制备方法
KR102121817B1 (ko) * 2018-09-12 2020-06-26 한국화학연구원 Crispr 편집 기술을 이용한 재조합 항원을 발현시키는 벡터 및 이를 동시에 다중 삽입시키는 방법
EP3849304B1 (en) 2018-09-13 2024-01-10 Regeneron Pharmaceuticals, Inc. Complement factor h gene knockout rat as a model of c3 glomerulopathy
EP3861120A4 (en) 2018-10-01 2023-08-16 North Carolina State University RECOMBINANT TYPE I CRISPR-CAS SYSTEM
CN113166754A (zh) 2018-10-16 2021-07-23 蓝色等位基因有限责任公司 用于将dna靶向插入基因中的方法
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
WO2020086475A1 (en) 2018-10-22 2020-04-30 Inscripta, Inc. Engineered enzymes
WO2020086908A1 (en) * 2018-10-24 2020-04-30 The Broad Institute, Inc. Constructs for improved hdr-dependent genomic editing
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
KR20210104068A (ko) 2018-12-14 2021-08-24 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 게놈 편집을 위한 신규한 crispr-cas 시스템
AU2019400930A1 (en) 2018-12-19 2021-07-01 King's College London Immunotherapeutic methods and compositions
IL301193A (en) 2018-12-20 2023-05-01 Regeneron Pharma Nuclease-mediated repeat expansion
MX2021008153A (es) * 2019-01-04 2021-08-11 Univ Chicago Sistemas y metodos para modular arn.
WO2020146899A1 (en) * 2019-01-11 2020-07-16 Chan Zuckerberg Biohub, Inc. Targeted in vivo genome modification
WO2020163396A1 (en) 2019-02-04 2020-08-13 The General Hospital Corporation Adenine dna base editor variants with reduced off-target rna editing
CN113728097A (zh) * 2019-02-14 2021-11-30 宏基因组学知识产权技术有限责任公司 具有ruvc结构域的酶
WO2020168102A1 (en) * 2019-02-15 2020-08-20 Sigma-Aldrich Co. Llc Crispr/cas fusion proteins and systems
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
DE212020000516U1 (de) * 2019-03-07 2022-01-17 The Regents of the University of California CRISPR-CAS-Effektorpolypeptide
JP7461368B2 (ja) 2019-03-18 2024-04-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タウの播種または凝集の遺伝的修飾因子を同定するためのｃｒｉｓｐｒ／ｃａｓスクリーニングプラットフォーム
JP7389135B2 (ja) 2019-03-18 2023-11-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タウ凝集に関連する遺伝的脆弱性を明らかにするためのｃｒｉｓｐｒ／ｃａｓドロップアウトスクリーニングプラットフォーム
AU2020242032A1 (en) 2019-03-19 2021-10-07 Massachusetts Institute Of Technology Methods and compositions for editing nucleotide sequences
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
EP3947691A4 (en) 2019-03-25 2022-12-14 Inscripta, Inc. SIMULTANEOUS MULTIPLEX GENOME EDITING IN A YEAST
AU2020256225A1 (en) 2019-04-03 2021-09-02 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
IL286905B1 (en) 2019-04-04 2024-02-01 Regeneron Pharma Non-human animals containing the human coagulation factor 12 locus
IL286917B (en) 2019-04-04 2022-09-01 Regeneron Pharma Methods for scar-free insertion of targeted modifications into targeted vectors
GB201905360D0 (en) 2019-04-16 2019-05-29 Univ Nottingham Fungal strains, production and uses thereof
US20220220495A1 (en) 2019-05-10 2022-07-14 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
EP3801011A1 (en) 2019-06-04 2021-04-14 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
AU2020288623A1 (en) 2019-06-06 2022-01-06 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
KR20220017939A (ko) 2019-06-07 2022-02-14 리제너론 파마슈티칼스 인코포레이티드 인간화 알부민 좌위를 포함하는 비-인간 동물
AU2020290509A1 (en) 2019-06-14 2021-11-11 Regeneron Pharmaceuticals, Inc. Models of tauopathy
US10907125B2 (en) 2019-06-20 2021-02-02 Inscripta, Inc. Flow through electroporation modules and instrumentation
CN114008070A (zh) 2019-06-21 2022-02-01 因思科瑞普特公司 导致大肠杆菌赖氨酸产量增加的全基因组合理设计的突变
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
WO2021050398A1 (en) * 2019-09-10 2021-03-18 The Regents Of The University Of California Synthetic lethality screening platform for cells undergoing alt
CA3150334A1 (en) 2019-09-12 2021-03-18 Frank Meulewaeter REGULATORY NUCLEIC ACID MOLECULES TO ENHANCE GENE EXPRESSION IN PLANTS
JP2022548031A (ja) 2019-09-13 2022-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 脂質ナノ粒子によって送達されるｃｒｉｓｐｒ／ｃａｓシステムを使用する動物における転写調節
WO2021069387A1 (en) 2019-10-07 2021-04-15 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
CN110628825A (zh) * 2019-10-14 2019-12-31 上海捷易生物科技有限公司 一种依赖nhej的报告基因敲入组合物及其使用方法
KR20220097414A (ko) 2019-11-08 2022-07-07 리제너론 파마슈티칼스 인코포레이티드 X-연관 연소 망막층간분리 치료법을 위한 crispr 및 aav 전략
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
AU2020396138A1 (en) 2019-12-03 2022-06-16 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
AU2020402526A1 (en) 2019-12-10 2022-06-09 Inscripta, Inc. Novel mad nucleases
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
WO2021122080A1 (en) 2019-12-16 2021-06-24 BASF Agricultural Solutions Seed US LLC Improved genome editing using paired nickases
US11008557B1 (en) 2019-12-18 2021-05-18 Inscripta, Inc. Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
EP4087600A4 (en) * 2020-01-09 2024-01-24 Pioneer Hi Bred Int TWO-STEP GENE EXCHANGE
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
WO2021154706A1 (en) 2020-01-27 2021-08-05 Inscripta, Inc. Electroporation modules and instrumentation
CN115175559A (zh) 2020-01-28 2022-10-11 瑞泽恩制药公司 包含人源化pnpla3基因座的非人动物及其使用方法
EP4099821A1 (en) 2020-02-07 2022-12-14 Regeneron Pharmaceuticals, Inc. <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
EP4114946A1 (en) 2020-03-04 2023-01-11 Regeneron Pharmaceuticals, Inc. Methods and compositions for sensitization of tumor cells to immune therapy
US20230102342A1 (en) 2020-03-23 2023-03-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
KR20220161383A (ko) 2020-03-31 2022-12-06 메타지노미, 인크. 클래스 ii, 유형 ii crispr 시스템
US20210319851A1 (en) 2020-04-03 2021-10-14 Creyon Bio, Inc. Oligonucleotide-based machine learning
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
US20230232796A1 (en) 2020-06-26 2023-07-27 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ace2 locus
CN111849986A (zh) * 2020-07-24 2020-10-30 江苏集萃药康生物科技有限公司 一种减少CRISPR-Cas9基因编辑中双链DNA片段串联的方法及其应用
US11299731B1 (en) 2020-09-15 2022-04-12 Inscripta, Inc. CRISPR editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
WO2022120022A1 (en) 2020-12-02 2022-06-09 Regeneron Pharmaceuticals, Inc. Crispr sam biosensor cell lines and methods of use thereof
US20240058390A1 (en) * 2020-12-16 2024-02-22 The Administrators Of The Tulane Educational Fund Wnt+ adipocytes, exosomes from wnt+ adipocytes, and methods of making and using them
AU2021415461A1 (en) 2021-01-04 2023-08-17 Inscripta, Inc. Mad nucleases
EP4274890A1 (en) 2021-01-07 2023-11-15 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
GB202103131D0 (en) 2021-03-05 2021-04-21 Biosystems Tech Limited Method for preparation of research organisms
EP4337769A1 (en) 2021-05-10 2024-03-20 SQZ Biotechnologies Company Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
KR20240027676A (ko) 2021-06-02 2024-03-04 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도
WO2023039586A1 (en) 2021-09-10 2023-03-16 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
WO2023064924A1 (en) 2021-10-14 2023-04-20 Codiak Biosciences, Inc. Modified producer cells for extracellular vesicle production
WO2023077053A2 (en) 2021-10-28 2023-05-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
WO2023077148A1 (en) 2021-11-01 2023-05-04 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
AU2022381205A1 (en) 2021-11-04 2024-03-28 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified cacng1 locus
CA3238939A1 (en) 2021-12-08 2023-06-15 Gaurang Patel Mutant myocilin disease model and uses thereof
GB202118058D0 (en) 2021-12-14 2022-01-26 Univ Warwick Methods to increase yields in crops
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
WO2023122506A1 (en) 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising humanized ace2 and tmprss loci
WO2023122764A1 (en) 2021-12-22 2023-06-29 Tome Biosciences, Inc. Co-delivery of a gene editor construct and a donor template
WO2023129974A1 (en) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Generation of landing pad cell lines
WO2023150181A1 (en) 2022-02-01 2023-08-10 President And Fellows Of Harvard College Methods and compositions for treating cancer
TW202332767A (zh) 2022-02-02 2023-08-16 美商雷傑納榮製藥公司 用於治療龐貝氏症之抗ＴｆＲ：ＧＡＡ及抗ＣＤ６３：ＧＡＡ插入
WO2023150798A1 (en) 2022-02-07 2023-08-10 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
WO2023212677A2 (en) 2022-04-29 2023-11-02 Regeneron Pharmaceuticals, Inc. Identification of tissue-specific extragenic safe harbors for gene therapy approaches
WO2023215831A1 (en) 2022-05-04 2023-11-09 Tome Biosciences, Inc. Guide rna compositions for programmable gene insertion
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023225665A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2023235725A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr-based therapeutics for c9orf72 repeat expansion disease
WO2023235726A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr interference therapeutics for c9orf72 repeat expansion disease
WO2023250384A2 (en) * 2022-06-22 2023-12-28 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
GB2621813A (en) 2022-06-30 2024-02-28 Univ Newcastle Preventing disease recurrence in Mitochondrial replacement therapy
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024026488A2 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified transferrin receptor locus
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024031053A1 (en) 2022-08-05 2024-02-08 Regeneron Pharmaceuticals, Inc. Aggregation-resistant variants of tdp-43
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024073606A1 (en) 2022-09-28 2024-04-04 Regeneron Pharmaceuticals, Inc. Antibody resistant modified receptors to enhance cell-based therapies
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024083579A1 (en) 2022-10-20 2024-04-25 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
WO2024098002A1 (en) 2022-11-04 2024-05-10 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
WO2024107765A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2024107670A1 (en) 2022-11-16 2024-05-23 Regeneron Pharmaceuticals, Inc. Chimeric proteins comprising membrane bound il-12 with protease cleavable linkers

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
WO1988008450A1 (en) 1987-05-01 1988-11-03 Birdwell Finlayson Gene therapy for metabolite disorders
US5350689A (en) 1987-05-20 1994-09-27 Ciba-Geigy Corporation Zea mays plants and transgenic Zea mays plants regenerated from protoplasts or protoplast-derived cells
US5767367A (en) 1990-06-23 1998-06-16 Hoechst Aktiengesellschaft Zea mays (L.) with capability of long term, highly efficient plant regeneration including fertile transgenic maize plants having a heterologous gene, and their preparation
US7150982B2 (en) 1991-09-09 2006-12-19 Third Wave Technologies, Inc. RNA detection assays
FR2763797B1 (fr) * 1997-05-30 1999-07-16 Tabacs & Allumettes Ind Cigarette a tres faible taux de goudron presentant un gout de tabac comparable a celui d'une cigarette classique a plus fort taux de goudron
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US20020182673A1 (en) 1998-05-15 2002-12-05 Genentech, Inc. IL-17 homologous polypedies and therapeutic uses thereof
EP1147209A2 (en) 1999-02-03 2001-10-24 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
US8183339B1 (en) * 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2002026967A2 (en) 2000-09-25 2002-04-04 Thomas Jefferson University Targeted gene correction by single-stranded oligodeoxynucleotides
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
JP3454818B1 (ja) * 2001-03-16 2003-10-06 直哉 小林 肝臓細胞の増殖方法、該方法により得られる肝臓細胞、およびその用途
KR20040022449A (ko) 2001-07-12 2004-03-12 유니버시티 오브 매사추세츠 유전자 불활성화를 매개하는 소형 간섭 ｒｎａ의 생체내제조
US20060253913A1 (en) 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
WO2003087341A2 (en) * 2002-01-23 2003-10-23 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
AU2003224897A1 (en) 2002-04-09 2003-10-27 Kenneth L. Beattie Oligonucleotide probes for genosensor chips
AU2003233719A1 (en) * 2002-06-06 2003-12-22 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Modifying the dna recombination potential in eukaryotes
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
DE10260805A1 (de) * 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
WO2005014791A2 (en) * 2003-08-08 2005-02-17 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8053232B2 (en) 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20050220796A1 (en) 2004-03-31 2005-10-06 Dynan William S Compositions and methods for modulating DNA repair
US7919277B2 (en) 2004-04-28 2011-04-05 Danisco A/S Detection and typing of bacterial strains
EP2316942B1 (en) * 2004-12-22 2021-04-21 Alnylam Pharmaceuticals, Inc. Conserved hbv and hcv sequences useful for gene silencing
US7892224B2 (en) 2005-06-01 2011-02-22 Brainlab Ag Inverse catheter planning
US7534819B2 (en) 2005-06-10 2009-05-19 University Of Washington Compositions and methods for intracellular delivery of biotinylated cargo
US20060282289A1 (en) 2005-06-14 2006-12-14 Healthmatch Solutions, Llc System and method for health care financing
WO2007014181A2 (en) * 2005-07-25 2007-02-01 Johns Hopkins University Site-specific modification of the human genome using custom-designed zinc finger nucleases
CN101273141B (zh) * 2005-07-26 2013-03-27 桑格摩生物科学股份有限公司 外源核酸序列的靶向整合和表达
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
ES2398918T3 (es) 2005-08-26 2013-03-22 Dupont Nutrition Biosciences Aps Un método y una ordenación para soportar verticalmente elementos de resistencia eléctrica pendientes
KR100877824B1 (ko) * 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
EP2522749A1 (en) * 2006-03-02 2012-11-14 The Ohio State University MicroRNA expression profile associated with pancreatic cancer
WO2007106690A2 (en) 2006-03-15 2007-09-20 Siemens Healthcare Diagnostics Inc. Degenerate nucleobase analogs
JP2009531444A (ja) * 2006-03-28 2009-09-03 ノバルティス アーゲー ＨＩＶＴＡＴタンパク質およびＥｎｖタンパク質の共有結合的に連結された複合体
WO2007128338A1 (en) 2006-05-10 2007-11-15 Deinove Process for chromosomal engineering using a novel dna repair system
DK2426220T3 (en) 2006-05-19 2016-09-26 Dupont Nutrition Biosci Aps Labeled microorganisms, and methods for labeling
EP2019839B1 (en) 2006-05-25 2011-12-07 Sangamo BioSciences, Inc. Methods and compositions for gene inactivation
DK2034848T3 (en) 2006-06-16 2017-02-06 Dupont Nutrition Biosci Aps STREPTOCOCCUS THERMOPHILUS BACTERIA
US8481272B2 (en) * 2006-08-04 2013-07-09 Georgia State University Research Foundation, Inc. Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity
ES2719789T3 (es) 2007-03-02 2019-07-16 Dupont Nutrition Biosci Aps Cultivos con resistencia mejorada a fagos
GB0806086D0 (en) 2008-04-04 2008-05-14 Ulive Entpr Ltd Dendrimer polymer hybrids
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
KR101759586B1 (ko) 2008-08-22 2017-07-19 상가모 테라퓨틱스, 인코포레이티드 표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물
ES2738980T3 (es) 2008-09-15 2020-01-28 Childrens Medical Ct Corp Modulación de BCL11A para el tratamiento de hemoglobinopatías
US20100076057A1 (en) * 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
US10662227B2 (en) 2008-11-07 2020-05-26 Dupont Nutrition Biosciences Aps Bifidobacteria CRISPR sequences
CN102264895B (zh) 2008-12-12 2015-01-28 杜邦营养生物科学有限公司 用于乳品发酵的具有独特流变性质的嗜热链球菌菌株的遗传簇
WO2010075424A2 (en) 2008-12-22 2010-07-01 The Regents Of University Of California Compositions and methods for downregulating prokaryotic genes
GB0823658D0 (en) 2008-12-30 2009-02-04 Angiomed Ag Stent delivery device
US8392349B2 (en) 2009-02-23 2013-03-05 Shalini Vajjhala Global adaptation atlas and method of creating same
WO2010117464A1 (en) 2009-04-09 2010-10-14 Sangamo Biosciences, Inc. Targeted integration into stem cells
EA023938B1 (ru) 2009-04-30 2016-07-29 Оспедале Сан Рафаэлле С.Р.Л. Вектор гена
US20120192298A1 (en) * 2009-07-24 2012-07-26 Sigma Aldrich Co. Llc Method for genome editing
JP2013500018A (ja) 2009-07-24 2013-01-07 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー ゲノム編集のための方法
EP2461819A4 (en) 2009-07-28 2013-07-31 Sangamo Biosciences Inc METHODS AND COMPOSITIONS FOR TREATING TRI-NUCLEOTIDE REPEAT DISORDERS
KR101418355B1 (ko) 2009-10-23 2014-07-11 (주)바이오니아 고밀도 유전자 합성기
DE102009052674B4 (de) 2009-11-12 2012-10-18 Karl Weinhold Verfahren und Vorrichtung zum Verbinden von Doppelmantelrohren
US20110294114A1 (en) 2009-12-04 2011-12-01 Cincinnati Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
AU2010327998B2 (en) 2009-12-10 2015-11-12 Iowa State University Research Foundation, Inc. TAL effector-mediated DNA modification
WO2011100058A1 (en) 2010-02-09 2011-08-18 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US10087431B2 (en) 2010-03-10 2018-10-02 The Regents Of The University Of California Methods of generating nucleic acid fragments
MX2012013037A (es) 2010-05-10 2013-07-29 Univ California Composiciones de endorribonucleasa y metodos de uso de las mismas.
WO2011146121A1 (en) 2010-05-17 2011-11-24 Sangamo Biosciences, Inc. Novel dna-binding proteins and uses thereof
EP2392208B1 (en) * 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use
WO2011156430A2 (en) 2010-06-07 2011-12-15 Fred Hutchinson Cancer Research Center Generation and expression of engineered i-onui endonuclease and its homologues and uses thereof
EP2580331A4 (en) 2010-06-14 2013-11-27 Univ Iowa State Res Found Inc NUCLEASE ACTIVITY OF THE TAL EFFECTOR AND FUSION PROTEIN FOKI
CN103168101A (zh) * 2010-07-23 2013-06-19 西格马-奥尔德里奇有限责任公司 使用靶向核酸内切酶和单链核酸的基因组编辑
US9081737B2 (en) 2010-08-02 2015-07-14 Integrated Dna Technologies, Inc. Methods for predicting stability and melting temperatures of nucleic acid duplexes
EA201390586A1 (ru) 2010-10-20 2014-11-28 ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС Последовательности crispr-cas lactococcus
US9403880B2 (en) * 2010-11-26 2016-08-02 Institut Pasteur Identification of a human gyrovirus and applications
WO2012087756A1 (en) 2010-12-22 2012-06-28 Sangamo Biosciences, Inc. Zinc finger nuclease modification of leucine rich repeat kinase 2 (lrrk2) mutant fibroblasts and ipscs
KR20120096395A (ko) 2011-02-22 2012-08-30 주식회사 툴젠 뉴클레아제에 의해 유전자 변형된 세포를 농축시키는 방법
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
AU2012312260B2 (en) 2011-09-21 2017-08-31 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
JP6144691B2 (ja) 2011-11-16 2017-06-07 サンガモ セラピューティクス， インコーポレイテッド 修飾されたｄｎａ結合タンパク質およびその使用
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
KR101833589B1 (ko) 2012-02-24 2018-03-02 프레드 헛친슨 켄서 리서치 센터 이상혈색소증 치료를 위한 조성물 및 방법
BR112014021104B1 (pt) 2012-02-29 2023-03-28 Sangamo Biosciences, Inc Proteína de fusão de ocorrência não natural compreendendo um domínio de ligação de dna de dedo de zinco manipulado que se liga a um gene htt, seu uso, método in vitro de modificação da expressão de um gene htt em uma célula, e método de geração de um sistema modelo para o estudo da doença de huntington
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
AU2013204327B2 (en) 2012-04-20 2016-09-01 Aviagen Cell transfection method
CN104245940A (zh) 2012-04-23 2014-12-24 拜尔作物科学公司 植物中的靶向基因组工程
PL2847335T3 (pl) 2012-04-25 2019-01-31 Regeneron Pharmaceuticals, Inc. Celowanie dużymi wektorami do celowania wspomagane nukleazą
NZ701060A (en) 2012-05-02 2016-10-28 Sangamo Biosciences Inc Targeted modification of malate dehydrogenase
RU2650819C2 (ru) 2012-05-07 2018-04-17 Сангамо Терапьютикс, Инк. Способы и композиции для опосредованной нуклеазой направленной интеграции трансгенов
WO2013169398A2 (en) 2012-05-09 2013-11-14 Georgia Tech Research Corporation Systems and methods for improving nuclease specificity and activity
DE202013012242U1 (de) * 2012-05-25 2016-02-02 Emmanuelle Charpentier Zusammensetzungen für die durch RNA gesteuerte Modifikation einer Ziel-DNA und für die durch RNA gesteuerte Modulation der Transkription
US20150376645A1 (en) 2012-05-30 2015-12-31 Baylor College Of Medicine Supercoiled minivectors as a tool for dna repair, alteration and replacement
US9102936B2 (en) 2012-06-11 2015-08-11 Agilent Technologies, Inc. Method of adaptor-dimer subtraction using a CRISPR CAS6 protein
RU2014153918A (ru) 2012-06-12 2016-07-27 Дженентек, Инк. Способы и композиции для получения условно нокаутных аллелей
EP2674501A1 (en) 2012-06-14 2013-12-18 Agence nationale de sécurité sanitaire de l'alimentation,de l'environnement et du travail Method for detecting and identifying enterohemorrhagic Escherichia coli
WO2013188638A2 (en) 2012-06-15 2013-12-19 The Regents Of The University Of California Endoribonucleases and methods of use thereof
CA2877290A1 (en) 2012-06-19 2013-12-27 Daniel F. Voytas Gene targeting in plants using dna viruses
JP6329537B2 (ja) 2012-07-11 2018-05-23 サンガモ セラピューティクス， インコーポレイテッド 生物学的薬剤の送達のための方法および組成物
WO2014011237A1 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
CN105188767A (zh) 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
EP2880171B1 (en) 2012-08-03 2018-10-03 The Regents of The University of California Methods and compositions for controlling gene expression by rna processing
KR102218562B1 (ko) 2012-08-29 2021-02-19 상가모 테라퓨틱스, 인코포레이티드 유전적 병태를 치료하기 위한 방법 및 조성물
UA118090C2 (uk) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
CN105264067B (zh) 2012-09-07 2020-11-10 美国陶氏益农公司 Fad3性能基因座及相应的能够诱导靶向断裂的靶位点特异性结合蛋白
UA119135C2 (uk) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб отримання трансгенної рослини
EP2906602B1 (en) 2012-10-12 2019-01-16 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
DE202013012597U1 (de) 2012-10-23 2017-11-21 Toolgen, Inc. Zusammensetzung zum Spalten einer Ziel-DNA, umfassend eine für die Ziel-DNA spezifische guide-RNA und eine Cas-Protein-codierende Nukleinsäure oder ein Cas-Protein, sowie deren Verwendung
AU2013337951B2 (en) 2012-10-30 2019-10-03 Recombinetics, Inc. Control of sexual maturation in animals
BR112015009812A2 (pt) 2012-10-31 2017-08-22 Cellectis Método para a inserção genética específica em um genoma de planta, célula de planta transformada e seu uso, planta resistente a herbicidas, kit, vetor, e célula hospedeira
US20140127752A1 (en) 2012-11-07 2014-05-08 Zhaohui Zhou Method, composition, and reagent kit for targeted genomic enrichment
PL3138910T3 (pl) 2012-12-06 2018-01-31 Sigma Aldrich Co Llc Oparta na CRISPR modyfikacja i regulacja genomu
WO2014093479A1 (en) 2012-12-11 2014-06-19 Montana State University Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
MX2015007549A (es) 2012-12-12 2017-01-20 Broad Inst Inc Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
EP3434776A1 (en) 2012-12-12 2019-01-30 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
US20140189896A1 (en) 2012-12-12 2014-07-03 Feng Zhang Crispr-cas component systems, methods and compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
JP6552965B2 (ja) 2012-12-12 2019-07-31 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための改善された系、方法および酵素組成物のエンジニアリングおよび最適化
PL2931898T3 (pl) * 2012-12-12 2016-09-30 Le Cong Projektowanie i optymalizacja systemów, sposoby i kompozycje do manipulacji sekwencją z domenami funkcjonalnymi
RU2678001C2 (ru) 2012-12-13 2019-01-22 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Способы обнаружения днк для сайт-специфической нуклеазной активности
WO2014099744A1 (en) 2012-12-17 2014-06-26 President And Fellows Of Harvard College Rna-guided human genome engineering
EP2938184B1 (en) 2012-12-27 2018-10-31 Keygene N.V. Method for removing genetic linkage in a plant
EP3919505B1 (en) 2013-01-16 2023-08-30 Emory University Uses of cas9-nucleic acid complexes
CN103233028B (zh) 2013-01-25 2015-05-13 南京徇齐生物技术有限公司 一种无物种限制无生物安全性问题的真核生物基因打靶方法及螺旋结构dna序列
WO2014127287A1 (en) 2013-02-14 2014-08-21 Massachusetts Institute Of Technology Method for in vivo tergated mutagenesis
EP2958990B1 (en) 2013-02-20 2019-10-16 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
EP2958996B1 (en) 2013-02-25 2019-10-16 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
WO2014150624A1 (en) 2013-03-14 2014-09-25 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
MX2015011985A (es) 2013-03-15 2016-04-07 Univ Minnesota Ingenieria genomica de plantas utilizando sistemas crispr/cas.
KR102210319B1 (ko) 2013-03-15 2021-02-01 더 제너럴 하스피탈 코포레이션 특정 게놈 좌위에 대한 유전적 및 후성적 조절 단백질의 rna-안내 표적화
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US20140364333A1 (en) 2013-03-15 2014-12-11 President And Fellows Of Harvard College Methods for Live Imaging of Cells
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
WO2014165825A2 (en) 2013-04-04 2014-10-09 President And Fellows Of Harvard College Therapeutic uses of genome editing with crispr/cas systems
CN105263312A (zh) 2013-04-05 2016-01-20 美国陶氏益农公司 用于在植物基因组内整合外源序列的方法和组合物
HUE040575T2 (hu) 2013-04-16 2019-03-28 Regeneron Pharma A patkány genom célzott módosítása
CN103224947B (zh) 2013-04-28 2015-06-10 陕西师范大学 一种基因打靶系统
US10604771B2 (en) 2013-05-10 2020-03-31 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
EP3778899A1 (en) 2013-05-22 2021-02-17 Northwestern University Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
US9873907B2 (en) 2013-05-29 2018-01-23 Agilent Technologies, Inc. Method for fragmenting genomic DNA using CAS9
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
KR20160034901A (ko) 2013-06-17 2016-03-30 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작에 최적화된 ｃｒｉｓｐｒ-ｃａｓ 이중 닉카아제 시스템, 방법 및 조성물
BR112015031608A2 (pt) 2013-06-17 2017-08-22 Massachusetts Inst Technology Aplicação e uso dos sistemas crispr-cas, vetores e composições para direcionamento e terapia hepáticos
RU2716421C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка, применение и применения в терапии систем crispr-cas и композиций для целенаправленного воздействия на нарушения и заболевания с использованием вирусных компонентов
WO2014204727A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
EP3011032B1 (en) 2013-06-17 2019-10-16 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
CN103343120B (zh) 2013-07-04 2015-03-04 中国科学院遗传与发育生物学研究所 一种小麦基因组定点改造方法
CN103382468B (zh) * 2013-07-04 2015-04-29 中国科学院遗传与发育生物学研究所 一种水稻基因组定点改造方法
SG10201913015XA (en) 2013-07-10 2020-02-27 Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
CN103388006B (zh) 2013-07-26 2015-10-28 华东师范大学 一种基因定点突变的构建方法
US10421957B2 (en) 2013-07-29 2019-09-24 Agilent Technologies, Inc. DNA assembly using an RNA-programmable nickase
US10233465B2 (en) 2013-11-04 2019-03-19 Dow Agrosciences Llc Optimal soybean loci
BR102014027438B1 (pt) 2013-11-04 2022-09-27 Dow Agrosciences Llc Molécula de ácido nucleico recombinante e método de produção de uma célula vegetal transgênica
US9909131B2 (en) 2013-11-04 2018-03-06 Dow Agrosciences Llc Optimal soybean loci
DK3066201T3 (en) 2013-11-07 2018-06-06 Editas Medicine Inc CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES
MX2016007654A (es) 2013-12-11 2017-08-15 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
US9850525B2 (en) 2014-01-29 2017-12-26 Agilent Technologies, Inc. CAS9-based isothermal method of detection of specific DNA sequence
WO2015117041A1 (en) 2014-01-30 2015-08-06 Nair Ramesh B Gene modification-mediated methods and compositions for generating dominant traits in eukaryotic systems
US20150225801A1 (en) 2014-02-11 2015-08-13 California Institute Of Technology Recording and mapping lineage information and molecular events in individual cells
US10370680B2 (en) 2014-02-24 2019-08-06 Sangamo Therapeutics, Inc. Method of treating factor IX deficiency using nuclease-mediated targeted integration
AU2015231353B2 (en) 2014-03-18 2020-11-05 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression

Also Published As

Publication number Publication date
ES2769310T3 (es) 2020-06-25
AU2019201344A1 (en) 2019-03-21
WO2014089290A1 (en) 2014-06-12
DK2928496T3 (da) 2019-11-11
PL3138911T3 (pl) 2019-04-30
EP3138912B1 (en) 2018-12-05
PL2928496T3 (pl) 2020-04-30
ES2713243T3 (es) 2019-05-20
ES2653212T3 (es) 2018-02-06
PL3138912T3 (pl) 2019-04-30
KR102479178B1 (ko) 2022-12-19
PL3363902T3 (pl) 2020-05-18
EP3363902A1 (en) 2018-08-22
KR20200098727A (ko) 2020-08-20
KR20230070065A (ko) 2023-05-19
KR20230003624A (ko) 2023-01-06
AU2020230243A1 (en) 2020-10-01
KR20180011351A (ko) 2018-01-31
AU2022200330B2 (en) 2023-11-09
HK1218389A1 (zh) 2017-02-17
PT3138910T (pt) 2017-10-18
US20210388396A1 (en) 2021-12-16
AU2020273316B2 (en) 2023-05-18
US20210079427A1 (en) 2021-03-18
AU2019201344C1 (en) 2020-12-24
US10745716B2 (en) 2020-08-18
US10731181B2 (en) 2020-08-04
BR112015012375A2 (pt) 2017-09-26
US20160017366A1 (en) 2016-01-21
EP3135765A1 (en) 2017-03-01
EP2928496A1 (en) 2015-10-14
ES2757808T3 (es) 2020-04-30
IL291129A (en) 2022-05-01
CA2891347C (en) 2018-02-27
US20160298133A1 (en) 2016-10-13
IL238856A0 (en) 2015-06-30
US20200140897A1 (en) 2020-05-07
KR102006880B1 (ko) 2019-08-02
DK3138911T3 (en) 2019-01-21
KR101844123B1 (ko) 2018-04-02
DK3138910T3 (en) 2017-10-16
JP6620018B2 (ja) 2019-12-11
EP3360964B1 (en) 2019-10-02
JP2016502840A (ja) 2016-02-01
PL3360964T3 (pl) 2020-03-31
IL257178A (en) 2018-03-29
US20160298136A1 (en) 2016-10-13
IL291129B2 (en) 2023-07-01
ES2757325T3 (es) 2020-04-28
JP2017192392A (ja) 2017-10-26
EP2928496A4 (en) 2017-03-01
CN105142669B (zh) 2018-07-03
JP2019037231A (ja) 2019-03-14
EP3360964A1 (en) 2018-08-15
EP3363902B1 (en) 2019-11-27
KR20150091052A (ko) 2015-08-07
CN108913676B (zh) 2023-11-03
CA3034794A1 (en) 2014-06-12
IL267598A (en) 2019-08-29
EP3138911B1 (en) 2018-12-05
CA2891347A1 (en) 2014-06-12
US20160298138A1 (en) 2016-10-13
AU2017204031A1 (en) 2017-07-06
KR102243092B1 (ko) 2021-04-22
IL300199A (en) 2023-03-01
AU2018229489B2 (en) 2018-12-06
LT3138911T (lt) 2019-02-25
SG10201800585VA (en) 2018-02-27
JP2021101706A (ja) 2021-07-15
AU2018229489A1 (en) 2018-10-04
JP7478772B2 (ja) 2024-05-07
DK3138912T3 (en) 2019-01-21
EP3138911A1 (en) 2017-03-08
IL267598B (en) 2022-05-01
PT3138911T (pt) 2018-12-28
ES2714154T3 (es) 2019-05-27
AU2020230246B2 (en) 2020-11-05
KR102531576B1 (ko) 2023-05-11
EP3617309A2 (en) 2020-03-04
DK3360964T3 (da) 2019-10-28
EP3617309A3 (en) 2020-05-06
DK3363902T3 (da) 2020-01-02
CN108715602A (zh) 2018-10-30
US20160298135A1 (en) 2016-10-13
PL3138910T3 (pl) 2018-01-31
US20210207173A1 (en) 2021-07-08
AU2020230243B2 (en) 2021-10-21
AU2017204031B2 (en) 2018-06-14
KR20190093680A (ko) 2019-08-09
CA2977152C (en) 2019-04-09
PT2928496T (pt) 2019-11-11
IL238856B (en) 2018-03-29
PT3138912T (pt) 2018-12-28
KR102145760B1 (ko) 2020-08-19
JP2022115994A (ja) 2022-08-09
EP3611263A1 (en) 2020-02-19
IL257178B (en) 2019-07-31
SG10202107423UA (en) 2021-08-30
LT3363902T (lt) 2020-02-10
AU2019201344B2 (en) 2020-09-03
LT3138912T (lt) 2019-02-25
EP2928496B1 (en) 2019-10-09
IL291129B1 (en) 2023-03-01
KR20210045515A (ko) 2021-04-26
SG11201503824SA (en) 2015-06-29
US20170073705A1 (en) 2017-03-16
AU2013355214B2 (en) 2017-06-15
JP2020120674A (ja) 2020-08-13
AU2020230246A1 (en) 2020-10-01
EP3138909A1 (en) 2017-03-08
PT3360964T (pt) 2019-10-29
AU2013355214A1 (en) 2015-06-04
US20160298134A1 (en) 2016-10-13
AU2023216829A1 (en) 2023-09-14
EP3138910B1 (en) 2017-09-20
CA2977152A1 (en) 2014-06-12
US20160298137A1 (en) 2016-10-13
US20160298125A1 (en) 2016-10-13
CN108913676A (zh) 2018-11-30
EP3138912A1 (en) 2017-03-08
US20160298132A1 (en) 2016-10-13
US20170191082A1 (en) 2017-07-06
AU2020273316A1 (en) 2020-12-17
LT3138910T (lt) 2017-11-10
PT3363902T (pt) 2019-12-19
EP3141604A1 (en) 2017-03-15
CN105142669A (zh) 2015-12-09
AU2022200330A1 (en) 2022-02-17
EP3138910A1 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
IL291129B1 (en) Crispr-based genome modification and regulation
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
IL237309A0 (en) Benzocyclooctyne compounds and uses thereof
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
HK1210949A1 (en) Combinations and uses thereof
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
EP2822601A4 (en) MIRNA AND USES THEREOF
GB201214645D0 (en) Algal genome modification
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201222342D0 (en) Compounds and uses thereof